GlassScriptPhysician profile
Bryan Tri Pham
NPI 1770150385
$1,672.82
in general payments reported to CMS, 2019-2025
21 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $122 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $280.80 | 2025 | Besremi |
| Janssen Biotech, INC. | $212.54 | 2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $181.43 | 2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $121.84 | 2025 | Xospata |
| Jazz Pharmaceuticals INC. | $121.82 | 2023 | |
| Sobi, INC | $73.49 | 2025 | |
| Beone Medicines USA, INC. | $57.34 | 2025 | Tevimbra, Brukinsa |
| Stemline Therapeutics INC. | $56.18 | 2025 | Orserdu, Elzonris |
| Servier Pharmaceuticals LLC | $55.47 | 2025 | |
| Iovance Biotherapeutics, INC. | $54.94 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $50.17 | 2025 | |
| Array Biopharma INC | $47.05 | 2025 | Xalkori, Lorbrena, Braftovi |
| Aveo Pharmaceuticals, INC. | $40.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.18 | 2025 | Ninlaro |
| Caris Mpi, INC. | $29.83 | 2025 | Mi Cancer Seek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.44 | 2025 | |
| Lilly USA, LLC | $24.19 | 2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $22.99 | 2025 | |
| Recordati_rare_diseases_inc. | $22.15 | 2025 | Panhematin |
| Rigel Pharmaceuticals, INC. | $19.41 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Astrazeneca Pharmaceuticals LP | $18.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.